STAT Plus: Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial
NIH
The small biotech says new clinical trial data suggest its experimental cancer drug improves the efficacy of Merck’s Keytruda. Eye roll.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario